E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil
…, GD Caldana, RA Zimerman… - Infection, Genetics and …, 2021 - Elsevier
The COVID-19 pandemic caused by SARS-CoV-2 has affected millions of people since its
beginning in 2019. The propagation of new lineages and the discovery of key mechanisms …
beginning in 2019. The propagation of new lineages and the discovery of key mechanisms …
[HTML][HTML] Genomic epidemiology of SARS-CoV-2 in Esteio, Rio Grande do Sul, Brazil
Background Brazil is the third country most affected by Coronavirus disease-2019 (COVID-19),
but viral evolution in municipality resolution is still poorly understood in Brazil and it is …
but viral evolution in municipality resolution is still poorly understood in Brazil and it is …
[HTML][HTML] Proxalutamide reduces the rate of hospitalization for COVID-19 male outpatients: a randomized double-blinded placebo-controlled trial
…, E Dorner, DC Onety, RA Zimerman… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
Antiandrogens have demonstrated a protective effect for COVOD-19 patients in observational
and interventional studies. The goal of this study was to determine if proxalutamide, an …
and interventional studies. The goal of this study was to determine if proxalutamide, an …
[HTML][HTML] Comparative genomics and characterization of SARS-CoV-2 P. 1 (gamma) variant of concern from Amazonas, Brazil
RA Zimerman, PAG Ferrareze, FA Cadegiani… - Frontiers in …, 2022 - frontiersin.org
Background P.1 lineage (Gamma) was first described in the State of Amazonas, northern
Brazil, in the end of 2020, and has emerged as a very important variant of concern (VOC) of …
Brazil, in the end of 2020, and has emerged as a very important variant of concern (VOC) of …
Efficacy of proxalutamide in hospitalized COVID-19 patients: a randomized, double-blind, placebo-controlled, parallel-design clinical trial
…, D do Nascimento Fonseca, J McCoy, RA Zimerman… - MedRxiv, 2021 - medrxiv.org
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity is
mediated by the androgen-promoted protease, transmembrane protease, serine 2 (TMPRSS2)…
mediated by the androgen-promoted protease, transmembrane protease, serine 2 (TMPRSS2)…
[HTML][HTML] Mutation hotspots and spatiotemporal distribution of SARS-CoV-2 lineages in Brazil, February 2020-2021
VB Franceschi, PAG Ferrareze, RA Zimerman… - Virus Research, 2021 - Elsevier
The COVID-19 pandemic has already reached more than 110 million people and is associated
with 2.5 million deaths worldwide. Brazil is the third worst-hit country, with approximately …
with 2.5 million deaths worldwide. Brazil is the third worst-hit country, with approximately …
Proxalutamide (GT0918) Reduces the rate of hospitalization in mild-to-moderate COVID-19 female patients: a randomized double-blinded placebo-controlled two-arm …
FA Cadegiani, RA Zimerman… - medRxiv, 2021 - medrxiv.org
Background Antiandrogens were shown to be effective in mild-tomoderate COVID-19 male
patients, supported by the SARS-CoV-2 dependency on transmembrane protease, serine 2 (…
patients, supported by the SARS-CoV-2 dependency on transmembrane protease, serine 2 (…
[HTML][HTML] Predominance of the SARS-CoV-2 lineage P. 1 and its sublineage P. 1.2 in patients from the metropolitan region of Porto Alegre, Southern Brazil in March …
…, LN Rotta, FA Cadegiani, RA Zimerman… - Pathogens, 2021 - mdpi.com
Almost a year after the COVID-19 pandemic had begun, new lineages (B.1.1.7, B.1.351, P.1,
and B.1.617.2) associated with enhanced transmissibility, immunity evasion, and mortality …
and B.1.617.2) associated with enhanced transmissibility, immunity evasion, and mortality …
Molecular evolution and structural analyses of the spike glycoprotein from Brazilian SARS-CoV-2 genomes: the impact of selected mutations
PA Gröhs Ferrareze, RA Zimerman… - Journal of …, 2023 - Taylor & Francis
The COVID-19 pandemic caused by SARS-CoV-2 has reached by February 2022 more
than 380 million cases and 5.5 million deaths worldwide since its beginning in late 2019, …
than 380 million cases and 5.5 million deaths worldwide since its beginning in late 2019, …
Proxalutamide (GT0918) reduction of mortality rate in hospitalized COVID-19 patients depends on treatment duration–an exploratory analysis of the proxa-rescue …
RA Zimerman, D do Nascimento Fonseca… - medRxiv, 2021 - medrxiv.org
Introduction Proxalutamide, a second generation non-steroidal antiandrogen (NSAA),
primarily developed for castration-resistant prostate cancer, demonstrated reduction in 28-day …
primarily developed for castration-resistant prostate cancer, demonstrated reduction in 28-day …
